57 related articles for article (PubMed ID: 21309037)
1. Characterization of MSH2 variants by endogenous gene modification in mouse embryonic stem cells.
Wielders EA; Dekker RJ; Holt I; Morris GE; te Riele H
Hum Mutat; 2011 Apr; 32(4):389-96. PubMed ID: 21309037
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of MSH2 unclassified variants found in suspected Lynch syndrome patients reveals pathogenicity due to attenuated mismatch repair.
Wielders EA; Hettinger J; Dekker R; Kets CM; Ligtenberg MJ; Mensenkamp AR; van den Ouweland AM; Prins J; Wagner A; Dinjens WN; Dubbink HJ; van Hest LP; Menko F; Hogervorst F; Verhoef S; te Riele H
J Med Genet; 2014 Apr; 51(4):245-53. PubMed ID: 24501230
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis in mouse embryonic stem cells reveals wild-type activity for three MSH6 variants found in suspected Lynch syndrome patients.
Wielders EA; Houlleberghs H; Isik G; te Riele H
PLoS One; 2013; 8(9):e74766. PubMed ID: 24040339
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis of HNPCC-related missense mutations in MSH2.
Lützen A; de Wind N; Georgijevic D; Nielsen FC; Rasmussen LJ
Mutat Res; 2008 Oct; 645(1-2):44-55. PubMed ID: 18822302
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of pathogenicity in human MSH2 missense mutants.
Ollila S; Dermadi Bebek D; Jiricny J; Nyström M
Hum Mutat; 2008 Nov; 29(11):1355-63. PubMed ID: 18951462
[TBL] [Abstract][Full Text] [Related]
6. A database to support the interpretation of human mismatch repair gene variants.
Ou J; Niessen RC; Vonk J; Westers H; Hofstra RM; Sijmons RH
Hum Mutat; 2008 Nov; 29(11):1337-41. PubMed ID: 18951442
[TBL] [Abstract][Full Text] [Related]
7. Two mismatch repair gene mutations found in a colon cancer patient--which one is pathogenic?
Kariola R; Otway R; Lönnqvist KE; Raevaara TE; Macrae F; Vos YJ; Kohonen-Corish M; Hofstra RM; Nyström-Lahti M
Hum Genet; 2003 Feb; 112(2):105-9. PubMed ID: 12522549
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants.
Houlleberghs H; Dekker M; Lantermans H; Kleinendorst R; Dubbink HJ; Hofstra RM; Verhoef S; Te Riele H
Proc Natl Acad Sci U S A; 2016 Apr; 113(15):4128-33. PubMed ID: 26951660
[TBL] [Abstract][Full Text] [Related]
9. Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression.
Shahrzad S; Quayle L; Stone C; Plumb C; Shirasawa S; Rak JW; Coomber BL
Cancer Res; 2005 Sep; 65(18):8134-41. PubMed ID: 16166287
[TBL] [Abstract][Full Text] [Related]
10. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
[TBL] [Abstract][Full Text] [Related]
11. [Mismatch repair (MMR) efficiency and MSH2 gene mutation in human colorectal carcinoma cell line COLO320HSR].
Tronov VA; Kramarenko II; Maĭorova EN; Zakharov SF
Genetika; 2007 Apr; 43(4):537-44. PubMed ID: 17555131
[TBL] [Abstract][Full Text] [Related]
12. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
13. A novel missense MSH2 gene mutation in a patient of a Korean family with hereditary nonpolyposis colorectal cancer.
Park SJ; Lee KA; Park TS; Kim NK; Song J; Kim BY; Choi JR
Cancer Genet Cytogenet; 2008 Apr; 182(2):136-9. PubMed ID: 18406877
[TBL] [Abstract][Full Text] [Related]
14. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene.
Banville N; Geraghty R; Fox E; Leahy DT; Green A; Keegan D; Geoghegan J; O'Donoghue D; Hyland J; Sheahan K
Hum Pathol; 2006 Nov; 37(11):1498-502. PubMed ID: 16996571
[TBL] [Abstract][Full Text] [Related]
15. MSH2 missense mutations and HNPCC syndrome: pathogenicity assessment in a human expression system.
Belvederesi L; Bianchi F; Galizia E; Loretelli C; Bracci R; Catalani R; Amati M; Cellerino R
Hum Mutat; 2008 Nov; 29(11):E296-309. PubMed ID: 18781619
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of pathogenic human MSH2 missense mutations in Saccharomyces cerevisiae.
Gammie AE; Erdeniz N; Beaver J; Devlin B; Nanji A; Rose MD
Genetics; 2007 Oct; 177(2):707-21. PubMed ID: 17720936
[TBL] [Abstract][Full Text] [Related]
17. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
[TBL] [Abstract][Full Text] [Related]
18. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC.
Ollila S; Fitzpatrick R; Sarantaus L; Kariola R; Ambus I; Velsher L; Hsieh E; Andersen MK; Raevaara TE; Gerdes AM; Mangold E; Peltomäki P; Lynch HT; Nyström M
Int J Oncol; 2006 Jan; 28(1):149-53. PubMed ID: 16327991
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer in an MSH2 gene mutation carrier.
Westenend PJ; Schütte R; Hoogmans MM; Wagner A; Dinjens WN
Hum Pathol; 2005 Dec; 36(12):1322-6. PubMed ID: 16311127
[TBL] [Abstract][Full Text] [Related]
20. New founding mutation in MSH2 associated with hereditary nonpolyposis colorectal cancer syndrome on the Island of Tenerife.
Medina-Arana V; Barrios Y; Fernández-Peralta A; Herrera M; Chinea N; Lorenzo N; Jiménez A; Martín-López JV; González-Hermoso F; Salido E; González-Aguilera JJ
Cancer Lett; 2006 Dec; 244(2):268-73. PubMed ID: 16500024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
